Compare Stocks

→ Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLBS Caladrius Biosciences		$6.37	$0.38 ▼ $1.24	$26.05M	0.91	522,308 shs	466,373 shs
SPE Special Opportunities Fund	$12.49 +0.8%	$12.43	$10.26 ▼ $12.73	$138.55M	1.01	27,673 shs	21,988 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLBS Caladrius Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
SPE Special Opportunities Fund	+0.81%	+0.24%	-1.19%	+2.97%	+14.38%

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SPE Special Opportunities Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A
SPE Special Opportunities Fund	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	$1.54 per share	N/A
SPE Special Opportunities Fund	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLBS Caladrius Biosciences	-$27.47M	-$0.41	N/A	N/A	N/A	N/A	-27.24%	-26.08%	N/A
SPE Special Opportunities Fund	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLBS Caladrius Biosciences	N/A	N/A	N/A	N/A	N/A
SPE Special Opportunities Fund	$1.08	8.65%	+16.50%	N/A	1 Years

Latest TAX, SPSY, SPE, and CLBS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/9/2024	SPE Special Opportunities Fund	monthly	$0.0954	9%	6/18/2024	6/18/2024	6/28/2024
4/8/2024	SPE Special Opportunities Fund	monthly	$0.0954	9%	5/20/2024	5/21/2024	5/31/2024
4/5/2024	SPE Special Opportunities Fund	Monthly	$0.0954	9.06%	5/20/2024	5/21/2024	5/31/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLBS Caladrius Biosciences	N/A	22.33	22.33
SPE Special Opportunities Fund	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
CLBS Caladrius Biosciences	15.57%
SPE Special Opportunities Fund	35.60%

Insider Ownership

Company	Insider Ownership
CLBS Caladrius Biosciences	2.20%
SPE Special Opportunities Fund	49.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CLBS Caladrius Biosciences	27	60.58 million	59.25 million	Optionable
SPE Special Opportunities Fund	N/A	11.18 million	5.67 million	Not Optionable

TAX, SPSY, SPE, and CLBS Headlines

Source	Headline
	Wolfinger Family Fund bolsters local school districts bradfordera.com - May 4 at 3:11 AM
	Why this family fund is investing the third time in a serial entrepreneur bizjournals.com - May 3 at 10:10 PM
	Anacostia Riverkeeper Clean Up Fund in jeopardy due to budget shortfall, riverkeeper fears msn.com - May 3 at 10:10 PM
	Gift allows Jasper County CASA to establish "Willcoxon Dream Big Fund" for foster children joplinglobe.com - May 3 at 10:10 PM
	The Saudi Fund for Development signs MoU to foster development prospects with the Republic of El Salvador zawya.com - May 3 at 8:19 AM
	ICIEC and KSA’s National Infrastructure Fund partner to boost infrastructure development in Saudi Arabia zawya.com - May 3 at 3:18 AM
	Philippine pension fund SSS eyes infrastructure co-investments with wealth fund Maharlika asiaasset.com - May 2 at 5:17 PM
	Latticework Capital Management Closes LCM Healthcare Fund II; Exceeds Target at $345 Million finance.yahoo.com - May 2 at 12:12 PM
	Artisan Dislocation Opportunities Fund Achieves Successful Final Close finance.yahoo.com - May 2 at 12:12 PM
	DOF supports partnership between BCDA, Maharlika fund to invest in Clark manilastandard.net - May 2 at 7:10 AM
	Foundation grants support special projects for Emmett teachers idahopress.com - May 1 at 2:56 AM
	Proposed Shelton budget could face $6M deficit because of empty surplus fund, finance members say sheltonherald.com - April 30 at 4:22 PM
	REALnorth Opportunities Fund Announces Interim Distribution to Unitholders as part of Wind-up of the Fund finance.yahoo.com - April 29 at 8:14 PM
	BCDA, Maharlika fund manager sign deal to explore investment projects manilastandard.net - April 29 at 3:13 PM
	Saudi Aramco Seeks Investment Opportunities in New Energies Abroad oilprice.com - April 29 at 3:13 PM
	Inside the investing strategy of Hunterbrook Capital, the news-driven hedge fund. Can it succeed in a ruthless industry? businessinsider.com - April 29 at 10:12 AM
	ASK Property Fund exits QVC Realty projects with 20% returns thehindubusinessline.com - April 29 at 10:12 AM
	AMCs eagerly pursue special opportunities funds: 3 firms file draft papers with SEBI dailyexcelsior.com - April 28 at 6:49 PM
	PM meets IMF chief at WEF special meeting in Riyadh tribune.com.pk - April 28 at 1:12 PM
	Why Doctors Are Turning to the Rise Capital Fund to Alleviate Their Tax Burden msn.com - April 28 at 8:11 AM
	AMCs eagerly pursue special opportunities funds; 3 firms file draft papers with Sebi zeebiz.com - April 28 at 8:11 AM
	Special Opportunities Fund, Inc. (NYSE:SPE) Short Interest Update marketbeat.com - April 27 at 7:56 PM
	After Concord bids $1.511bn for Hipgnosis Songs Fund, Blackstone tells HSF shareholders: Don’t move a muscle, we’ll be right back musicbusinessworldwide.com - April 27 at 12:03 AM
	United Negro College Fund Celebrates Its 80th Birthday blackenterprise.com - April 26 at 7:03 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Hasbro’s Management Made All the Right Calls This Quarter
April 25, 2024 11:16 AM
View Hasbro’s Management Made All the Right Calls This Quarter
Silicon Motion Proves That AI in Motion Stays in Motion
April 16, 2024 11:42 AM
View Silicon Motion Proves That AI in Motion Stays in Motion
Consumer Spending and Sentiment Rises: Time to Buy the XLY?
April 4, 2024 12:13 PM
View Consumer Spending and Sentiment Rises: Time to Buy the XLY?
J.B. Hunt Hits the Skids: Lower Prices to Come
April 17, 2024 12:28 PM
View J.B. Hunt Hits the Skids: Lower Prices to Come
PriceSmart Could Be the Smartest Buy of the Year
April 11, 2024 7:35 AM
View PriceSmart Could Be the Smartest Buy of the Year

All Headlines

Company Descriptions

Caladrius Biosciences

NASDAQ:CLBS

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Special Opportunities Fund

NYSE:SPE

Special Opportunities Fund, Inc. is a close-ended balanced fund of funds launched and managed by Bulldog Investors, LLC. It invests in close-ended funds investing in public equity and fixed income markets. The fund employs a combination of value, opportunistic and special situations strategies to make its investments. It benchmarks the performance of its portfolio against the S&P 500 Index. The fund was previously known as Insured Municipal Income Fund, Inc. Special Opportunities Fund, Inc. was formed on February 18, 1993 and is domiciled in the United States.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial